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Abstract 
There are a group of diseases associated with protein misfolding and accumulation into 
amyloid fibers. Many of these diseases have a major impact on human health, in particular, 
Alzheimer’s (AD), Parkinson’s (PD) and Prion diseases. The focus of this review is to highlight 
how metal ions influence amyloid formation in a number of neurodegenerative diseases.  
Firstly, the various mechanisms by which metal ions might influence the kinetics of amyloid 
fiber formation are surveyed.  The coordination of metal ions to a number of amyloidogenic 
proteins, with an emphasis on metal binding to intact fibers is reviewed. The kinetics of 
amyloid formation and the influence Cu
2+
, Zn
2+
, Fe
3+ 
and Ca
2+
 have on amyloid-beta peptide 
(A fiber formation in AD is described in detail.  The effect of metal ions on fibril formation 
for other amyloidogenic proteins, in particular Cu
2+ 
binding to -synuclein (Syn) and the 
prion protein (PrP), are also reviewed.  The mechanism by which metal ions might influence 
neurotoxicity of amyloids is also discussed.  Levels of metal ions found at the synapse are 
described and related to the affinity of metal ions for A, PrP and Syn.  In vivo evidence for a 
link between metal ions in these common neurodegenerative diseases, and the interplay 
between A the prion protein and copper are reported.  Finally, the possibility of a shared 
mechanism by which metal ions might influence amyloidosis is discussed.   
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1) Protein Misfolding Diseases 
Central to a number of neurodegenerative diseases and other diseases of protein accumulation 
and amyloidosis is the misfolding of individual proteins [1].  In Alzheimer’s disease (AD), the 
most common form of dementia, a small ~42 residue peptide, amyloid-beta peptide (A), is 
cleaved from a larger amyloid precursor protein (APP).  It is the accumulation of the A 
molecules into toxic oligomers and amyloid fibers that appears fundamental to the cascade of 
events, including the formation of neurofibrillary tangles of tau protein, central to the aetiology 
of AD dementia [2]. Similarly, in Parkinson’s Disease (PD) the natively unstructured protein, 
-Synuclein (Syn), accumulates into -sheet rich fibers within intra-cellular inclusion bodies, 
known as Lewy Bodies [3].  While misfolding of the mammalian prion protein (PrP) causes a 
group of transmissible spongiform encephalopathies (TSEs) in humans and other mammals [4].  
The misfolding of the proteins triggers a cascade of events in these diseases, often including the 
accumulation of ordered fiber aggregates of these proteins, with amyloid structure rich in -
sheet [1].  Genetic alterations underlying familial forms of these diseases are associated with 
mutations or increased production of A, PrP and Syn, indicating that these proteins play a 
central role in their respective diseases [3-5].  All three of these diseases have been linked to 
metal ion binding and changes in metal homeostasis [6, 7]. Other protein misfolding diseases 
will be briefly discussed within this review because of their association with metal ions. 
 
2) How can metal ions induce protein misfolding and accumulation? 
The influence of metal ions on protein misfolding does not require an external environmental 
influence, simply a perturbation in metal ion homeostasis and compartmentalization [6-9].  The 
Cu
2+
 and Zn
2+
 ions are found concentrated within senile plaques of Alzheimer’s disease 
patients directly bound to A [10-13]. In PD, elevated levels of copper and iron ions have been 
reported in the cerebrospinal-fluid and Lewy bodies respectively [14, 15].  In the case of the 
prion protein (PrP
C
), Cu
2+
 ions are known to bind to in vivo and in vitro [16, 17] and influences 
prion protein levels in the brain [18].  Metal imbalance is an early charcteristic of prion disease 
[19] and Cu
2+
 has been found in scrapie isolates (PrP
Sc
) and confers prion strain type [20].    
 
Concentration of these metal ions in amyloid fibers raises the possibility that these ions might 
trigger or promote amyloid formation.  There are a number of ways the coordination of metal 
ions can influence fiber generation. These possible processes are illustrated in Figure 1.  For 
example, the coordination might cause rearrangement of the protein main-chain and so trigger 
misfolding and subsequent protein accumulation, Figure 1.  Cu
2+
 binding to 2-microglobulin 
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(2M) has been shown to cause a key proline cis-trans isomerization, triggering misfolding and 
protein assembly in dialysis-related amyloidosis [21].  Coordination of the metal ion might 
involve inter-molecular cross-linking, Figure 1.  Formation of dimers or high order oligomeric 
forms may again influence the protein misfolding and accumulation.  For example, in vitro 
Zn
2+
 can form an inter-molecular complex with A, cross-linking between histidine residues on 
multiple A molecules, that inhibits fibrillization [22-24].  Coordination of a metal ion will 
typically affect the net charge of the protein, adding positive charge from the metal ion or 
losing charge from multiple deprotonation.  As a consequence, a protein with an acidic pI may 
become more neutrally charged and therefore more prone to self-association.  This mechanism 
is proposed to accelerate fiber formation kinetics when Cu
2+
 binds to A [23].  Amyloid fibers 
are in equilibrium with monomeric and oligomeric forms; it is possible that the metal ions 
might stabilize the fibril or oligomers once formed, by for example, cross-linking via the metal 
ion.  Alternatively, coordination of the metal ion could destabilize the normal non-pathogenic 
structure and so make misfolding more energetically favorable, Figure 1.  This has been shown 
to occur when Cu
2+
 binds to the normal cellular form of the prion protein [25].  The fibril 
morphology might also be influenced by metal ions.  Fe
3+
 ions have been shown to influence 
the morphology and toxicity of A fibers [26] while Cu2+ influences prion strain type [20].    
 
Furthermore, coordination of redox active metal ions, such as copper and iron might also 
influence protein accumulation by metal catalyzed chemical modification of the protein.  For 
example, reactive oxygen species (ROS) have been shown to generate an A dimer by covalent 
cross-linking of tyrosine residues within A [27].  Oxidation of the methionine and histidine 
residues have been reported for both A and PrP [28, 29].  The majority of the methionine in 
A (Met35) is oxidized within amyloid plaques [10].   While a large proportion of isolated 
scrapie (misfolded) prion protein is known to contain methionine residues oxidized to 
methionine-sulphoxide [30]. The chemical modification will in turn influence the stability, 
fiber forming kinetics and structure of the protein.   
 
3) The relationship between fibers, oligomers and neurotoxicity  
Initially mature amyloid fibers found in AD patients were identified as the neurotoxic entity in 
AD pathology, this concept was modified when it was found that small diffusible oligomers of 
A, rather than mature amyloid fibers were the more toxic form [31-33].  However a role for 
fibers in A neurotoxicity should not be ignored, as there remains strong evidence suggesting 
amyloid plaques, or possibly intermediates of the A fibrils, play a critical role [34, 35].  Small 
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oligomers rather than mature fibrils have also been highlighted as the most neourotoxic form 
for a number of other misfolding diseases [36]. Protein oligomers may be precursors to fiber 
formation but may also arise from fiber fragmentation [37].  Studying oligomers is extremely 
challenging as they tend to form heterogeneous mixtures and are often transient in nature.   The 
toxic oligomers may share the same structural features as larger fibers, the increased toxicity 
may simply arise from an increase in the number of toxic elements per total protein mass [37].  
A range of oligomeric forms have been identified with various structural features and oligomer 
sizes, which can be classified into pre-fibrilar oligomers, fibrillar oligomers and anular 
protofibrils using their antibody binding properties [33].  These oligomers can be on or off the 
pathway to fibers, in addition not all oligomers are cytotoxic.  Both fibers and oligomers 
require the self-association of protein, thus factors that affect fibrillisation will also influence 
oligomer generation.  Furthermore, amorphous aggregates, oligomers and fibers are all in 
equilibrium with the monomeric protein, thus stabilization or destabilization of one will perturb 
levels of the other.  The equilibrium set-up between different forms is illustrated in Figure 2. 
 
Although it may be that oligomers are the most toxic to cells, it appears that the rate of fibril 
formation in vitro can be strongly correlated with rates of disease progression in patients and 
animal models of the disease. This may be because conditions that promote amyloid formation 
also promote oligomers. For example, the familial early onset AD, associated with A 
mutations (E22K/G/Q) show considerably accelerated fibril growth times relative to the wild-
type sequence [38].  Furthermore, the disease associated A(1-42) is much more prone to 
rapidly forming fibers than A(1-40). Similarly, mutations in Syn associated with familial PD 
cause accelerated kinetics of fiber formation [39]. 
 
Despite significant progress in identifying misfolding proteins as central to the aetiology of a 
number of neurodegentrative diseases, the mechanism by which misfolded proteins are toxic is 
still not well established. The toxic action of may be intracellular, disrupting the mitochondrial 
membrane for example [32]. However, one popular hypothesis involves oligomers and fibers 
acting on the outer plasma membrane surface to disrupt membrane integrity [32].   The growing 
ends of fibers with exposed hydrophobic residues may be the region that perturbs membrane 
integrity.  Furthermore,  reactive oxygen species (ROS) generated at the membrane can cause 
lipid per-oxidation to further compromise the membrane [40].  The enhanced cytotoxic effects 
of Cu
2+
 bound to A might be explained by concentrating redox active Cu2+ ions at the plasma 
membrane surface where they will generate harmful ROS [23, 41].  A recent study has 
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highlighted the role for PrP
C
 in mediating A neuronal toxicity and describes how copper 
influences this process [42]; for more details see section 10.3. 
 
4) Amyloid fiber structure and metal ion coordination  
Amyloid fibers are typically un-branched fibers 7-12 nm thick and many microns long with a 
high proportion of -sheet structure. The beta strands stack perpendicular to the long axis of the 
fiber forming intermolecular hydrogen bonds, this type of structural motif is known as a cross-
beta structure.  A range of biophysical methods have been applied to studying the structure of 
fibers.  They include, X-ray fiber diffraction, solid-state NMR, cryo-EM, deuterium exchange 
and EPR of spin labels.  The biophysical approaches and structural features of various amyloids 
have been reviewed [43-45]. The morphology of fibers and consequently their pathology can 
vary depending on the conditions in which the fibers form, metal ions will affect the 
morphology or ‘strain’ of fibers [20, 26].    
 
The coordination of metal ions to a number of amyloidogenic proteins have been studied 
extensively.  For recent reviews in the area of A see [46-49], for the prion protein [50, 51] 
and for Syn [52].  
 
4.1) Cu
2+
-A structure: Cu2+ binding to A shows that one mole equivalent of Cu2+ bound to 
monomeric or mature A fibers have identical coordination geometries [53, 54] and affinities 
[53].  The -pleated core of A fibers occurs between residues 14 to 40, Cu2+ coordinating 
ligands falls just on the edge of this region.  Solid-state NMR of the Cu
2+ 
complex suggests that 
the fibrillar structure is not disrupted by Cu
2+
 coordination [55], figure 3.  The A peptide 
contains three histidine residues (His
6
, His
13
, His
14
), which along with the N-terminal amino 
group and aspartate form a tetragonal complex with Cu
2+
 ions [53, 54, 56-64].   A considerable 
amount of effort has been devoted to understanding the coordination geometry of Cu
2+
 bound 
to A and is the subject of a number of reviews[46-48].  Some of the details of the complex 
are yet to be agreed upon, and the model shown in Figure 3 [53] is only one of a number related 
structures suggested in the recent literature. A dynamic view of the Cu
2+
 complex involving 
imidazole coordination in both the axial and equatorial plain has now emerged [53, 57, 64, 65]. 
A numbers of interchangeable Cu
2+
 complexes from with related coordination geometries and 
different histidine sidechains in the equatorial plain and pH effecting their relative distribution 
[53, 57, 64, 65].  
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4.2) Cu-PrP structure: Less well understood is Cu
2+
 binding to the fibrillar form of PrP.  
Models of recombinant PrP amyloid fibers suggest that the core residues forming -strands 
within PrP are between residues 160-225 [66, 67].  Thus in amyloid fibers the Cu
2+
 binding N-
terminal residues (23-126) remain unstructured and may well bind Cu
2+
 with a similar 
coordination geometry as the cellular mammalian PrP, but this remains to be established.  
 
Metal binding, Cu
2+
 in particular, has been studied extensively for the cellular monomeric prion 
protein, PrP
C
.  As many as six Cu
2+
 ions coordinate to the natively unstructured N-terminal half 
of mammalian PrP
C
 at physiological pH.  The structured C-terminal domain of PrP
C
 does not 
affect Cu
2+
 coordination, as its removal does not affect binding to the natively unstructured N-
terminal domain, PrP(23-126) [16].  Cu
2+
 loads onto full-length PrP
C
 sequentially; the first 
equivalents of Cu
2+
 bind to the amyloidogenic region of PrP
C
, residues 90-126, followed by 
binding to the octarepeat region, residues 58-91 [16]. There are various binding modes, all 
involve tetragonal coordination to one or more histidine imidazole nitrogens.   
 
PrP contains a repeating motif of eight amino acids, between residues 58 and 91, with each 
repeat containing a histidine residue.  This highly conserved region binds up to four Cu
2+
 ions 
with identical coordination geometry [68, 69], Figure 3.  A crystal structure of the Cu
2+
 bound 
octarepeat motif (residues HGGGW) indicates square-pyramidal geometry [70] involving 
coordinating nitrogen and oxygen ligands from the main-chain as well as the imidazole 
sidechain. A more complete picture of the modes of Cu
2+
 coordination shows that at sub-
stoichiometric levels, Cu
2+
 ions will bind with a higher affinity to the octarepeats via multiple 
histidine residues [71-74], Figure 3.  
 
Cu
2+
 ions binding outside the octarepeat region are centered at His
95
 and His
110
 (His
96
 and 
His
111
 in the human sequence) [75-84].  A square-planar/tetragonal complex is formed upon 
Cu
2+
 binding, which involves the histidine imidazole nitrogen N and the main-chain amides 
that precede the histidine [79, 80], Figure 3.  This type of complex is similar to that in the 
octarepeats but is more stable because it involves a six membered chelate ring to the imidazole 
nitrogen rather than seven, Figure 3. There is reasonable agreement in the literature regarding 
the Cu
2+-
PrP binding modes.  The coordination geometries shown in Fig 3b may be a 
simplification of the coordination modes, as with the Cu-A complex a number of related 
complexes may form interchangeably and their relative abundance will depend on the pH and 
levels of Cu
2+
.  Indeed sub-stoichometric Cu
2+
 and lower pH values favor multiple histidine 
sidechain coordination [16, 71-74, 80]. Affinity measurements place the Kds, at pH 7.4, for 
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Cu
2+
 binding in the amyloidogenic region and octarepeats (multiple histidine binding mode) at 
30 nM, tighter than Cu
2+
 binding to individual octa-repeats (90 nM) [85].  Although, others 
have reported tighter binding in the multiple His binding mode [71-73], suggesting Cu
2+
 will 
bind here first rather than concomitantly with Cu
2+
 binding centered at His
110
 [16].  

Cu-Syn structure: Syn is largely found in presynaptic terminals in the reducing 
environment of the csytosol, here Syn will experience Cu+.  There have been some studies of 
Cu
+
 coordination to  Syn [86].  However, a proportion of Syn is found extra-cellularly, 
secreted by neuronal cells [87, 88], and so Cu
2+
 binding may also be relevant and has been 
studied more extensively.  The coordination geometry and affinity of Cu
2+
 ions to Syn has 
been characterized by a number of groups.  A range of spectroscopies including absorption, 
visible-CD and EPR has been used to characterize the coordination geometry [89].  While the 
paramagnetic broadening effects of Cu
2+
 has been studied using solution NMR [90].  Redox 
properties and coordination of the synuclein family of proteins have also been described [91, 
92].  EPR and pulsed EPR methods have been used to carefully characterize the Cu
2+
 
coordination to full-length natively unstructured Syn [93, 94].   It seems clear the main locus 
of binding to Syn is at the N-terminal amino group.  At pH 7.4, two related tetragonal 
complexes dominate, with almost equal affinity. Both modes of coordination involve the N-
terminal amino-group and the amide main-chain nitrogen and carboxylate side coordination 
from aspartate (Asp) at position 2.  Mode 1 is indicative of 2N2O ligands ( Mode 1:NH3, Namide 
CCOO, and water)  while Mode 2 is more indicative of 3N1O ligands and may possibly 
contain an imidazole nitrogen His51 to form a macrochelate to replace water coordination 
(Mode 2: NH3, Namide , CCOO, Hisimd) [93-95].  Recently a related Cu
2+
 complex is described 
at pH 6.5 [96].  The affinity for Syn is 0.1-0.4 nanomolar [94, 97, 98] while other metal ions 
have weaker mM affinities for Syn [99].   It is notable that the formation of amyloid fibers of 
Syn may not restrict Cu2+ coordination centered at the N-terminal amino group. 
 
4.4) Common feature of Cu
2+
and Zn
2+
 coordination: A feature of all three of these Cu
2+
 
binding proteins is that the binding region is natively unstructured, thus the coordination site is 
not preformed but there is a structural rearrangement as the Cu
2+
 binds to the protein.  All 
involve at least one imidazole nitrogen to form a tetragonal complex. A feature of PrP and 
Syn is main-chain amide coordination to the Cu2+, which makes these binding sites quite 
specific to Cu
2+
 ions as few other metal ions are capable of amide deprotonation [79, 80, 100].   
Zn
2+
 binding to proteins does not typically mimic the Cu
2+
 coordinating ligands.  In particular, 
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Zn
2+
 is not able to coordinate amide main-chain nitrogen.  In addition, Zn
2+
 ions form 
tetrahedral complexes rather than tetragonal.  There is evidence of Zn
2+
 causing inter-molecular 
cross-linking of imidazoles within A molecules and multiple His imidazole coordination from 
the octarepeats of PrP [22, 46, 63, 101]. 
 
5) Kinetics of fiber formation:  
5.1) Nucleation-dependant polymerization:   
The kinetics of amyloid fiber formation are often described as a nucleation-dependant 
polymerization reaction [1].  This process involves the protein monomer forming a nucleating 
‘seed’, this is then followed by a more rapid self-templated growth where the ends of existing 
fibers recruit protein monomer and so extend fiber length.  There is still debate as to the precise 
nature of the minimal form of protein that nucleates fiber formation.  Suggestions range from 
misfolded monomeric species, dimer, penta to larger oligomers. 
 
In vitro, the kinetics of fiber formation typically follows a sigmoidal fiber growth curve, Figure 
4 [44, 102]. Key observables include the lag-phase (nucleation) and the maximal growth rate 
(elongation).  Fiber growth then plateaus, reaching equilibrium with low amounts of monomer, 
known as the critical concentration of fiber formation.  A key feature of the nucleation-
dependant polymerization reaction, is the ability of small amounts of pre-formed fibrils to 
‘seed’ the reaction reducing the lag-phase significantly, Figure 4. 
 
It is well established in vitro that kinetics of fiber formation are also often strongly influenced 
by agitation or sonication, which will cause significant fragmentation of fibers. It is now clear 
that a secondary nucleation process, in particular fragmentation, can significantly reduce the 
observable lag-time. The fragmentation-assisted growth has the effect of self-seeding fibril 
formation and can dominate the kinetics of fibril growth [103].  
 
5.2) Monitoring Fiber Kinetics:  
There are various methods by which the kinetics of fiber formation can be monitored in-vitro 
[102] .  These include measuring a change in structure as -sheets form within the fiber (via, 
for example, CD) or change in particle size via dynamic light scattering.  A common approach 
is to use fiber specific dyes.  In particular, Thioflavin T (ThT) which when bound to amyloid 
fibers fluoresces at 487 nm [102].  This fluorescence signal is directly related to the amount of 
amyloid present. The kinetics of fiber growth are very sensitive to a number of factors such as 
pH, concentration, agitation, temperature and ionic strength, these must be carefully controlled 
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in vitro for direct comparisons.   Solubilisation of the protein or peptide into a seed-free form is 
also important. Typically, a fluorescence well-plate reader is used for the ThT measurements so 
that repeat fiber growth measurements can be made under identical conditions for a direct 
comparison.   
 
5.3) Growth Curve Analysis:  
The fiber growth curve, Figure 4, can provide a number of empirical parameters, these 
including lag-time (tlag), the apparent rate of elongation (kapp) and the time taken to reach half 
maximal fibre intensity (t50). The fiber growth curve can be fitted to the following equation 
[104].  
 
   Y=  (yi + mix)  +     (f + mfx)                   (eq 1) 
                               (1 + exp
-(X-Xo/) 
) 
 
Where Y is the fluorescence intensity, x is the time and X0 is the time at half height of 
fluorescence (t50). The kapp and tlag can be obtained from 1/ and X0-2 respectively. Others 
have obtained alternative empirical parameters [105] and a set of master equations to describe 
the kinetics of fiber formation have been proposed [103]. 
 
6) Metal ions and A fiber formation in AD   
6.1) Cu
2+
 and A, self-association, amorphous aggregation versus fibrillization: 
Two studies over a decade ago showed that Zn
2+
 and Cu
2+ 
ions caused marked aggregation of 
the A peptide[106-108]. However, these initial studies did not make the distinction between 
amorphous aggregates, which are thought to be non-toxic to cells, and the formation of amyloid 
fibers.  Further investigations using the fiber specific fluorophore,  thioflavin T (ThT), 
suggested that Cu
2+
 and Zn
2+
 only promote amorphous aggregation of A and actually inhibit 
fiber formation  [109-113].   Some of the confusion and misunderstanding in the literature 
surrounding the area can largely be attributed to using the word ‘aggregation’ and 
‘fibrillization’ interchangeably.   There are a number of studies now published that carefully 
characterize the promotion and nature of amorphous aggregates generated in the presence of 
Cu
2+
  [24, 112-115].  Studies using primary cell culture and immortal cell lines suggest Cu
2+
 
induced amorphous aggregates are non-toxic to cells [109, 112]. 
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In contrast to these studies, others have shown that at sub-stoichiometric levels of Cu
2+
 ions A 
amyloid fiber formation is not inhibited, while supra-stoichiometric levels of Cu
2+
 ions promote 
amorphous aggregates, however the kinetics of fiber formation were not investigated [27, 116]. 
A key study by Sarell et al showed that sub-stoichiometric levels of Cu
2+
 will actually 
significantly accelerate the kinetics of fiber formation, consistently reducing the lag-time of 
fiber formation of A(1-40) by more than half [23].  Figure 5 shows A fiber growth kinetics,  
metal-free A preparations typically take more than 70 +/- 2 hours to reach half maximal 
fluorescence (t50), while the same A preparations with 0.5 or 1 mole equivalent of Cu
2+
 ions 
cause fibers to form in nearly half the time; 38 +/- 2 hours, at pH 7.4. The lag-time is reduced 
by Cu
2+
 ions, from 49 to 16 hours.  Sub-stoichiometric amounts of Cu
2+
 between 0.2-0.4 mole 
equivalents display the greatest increase in fiber growth rates.  This supports the hypothesis that 
Cu
2+
 accelerates nucleation as small sub-stoichiometric amounts of Cu
2+
 can nucleate fiber 
formation.  Further addition of Cu
2+
 ions beyond one mole equivalent caused precipitation of 
A and markedly reduces the amount of fibres generated [23], as previously noted [27, 116].  
Furthermore, at high concentrations of A(1-40) even sub-stoichiometric amounts of Cu2+ will 
inhibit fiber formation [23, 110, 115].  It is now clear that at sub-stoichiometric levels of Cu
2+
 
to A and more dilute concentrations of A, Cu2+ will accelerate the kinetics of fiber 
formation.  While at supra-molecular levels of Cu
2+
 to A or high concentrations of A (40 
micro-molar A40) [23, 115] fiber formation is inhibited. At these conditions, TEM and AFM 
studies indicate that amorphous aggregation is promoted at the expense of amyloid fiber 
formation [24, 112, 113, 115].  Substoichiometric amounts of Cu
2+
 were also shown to promote 
A(1-42) fiber formation [23], although others have not observed fiber inhibition under quite 
similar conditions [112]. A(1-42) is markedly less soluble than A(1-40) and so the 
completion favoring amorphous aggregation over fiber formation must be more pronounced.  
Table 1 highlights some of the studies performed investigating the effect of Cu
2+
 on A(1-40) 
and A(1-42) fiber formation, highlighting the different effects of Cu2+ and A concentrations.  
 
The process of generating amyloid fibers (described as nucleation dependent polymerization) 
has many parallels with protein crystallization [1].  Like amyloid fibril formation crystallization 
can also be accelerated by a nucleating ‘seed’. With protein crystallization, the concentration of 
the protein, the pH of the solution, and the levels of salts are adjusted to maximize self-
association of the protein molecules into ordered crystals.  If conditions are created that are too 
self-associating for the protein then amorphous aggregates are generated rather than crystals, 
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this is also true in fibrillization; self-association must occur for ordered fibers to form, however, 
if conditions are too self-associating amorphous aggregates are generated.  
 
The amorphous aggregates of Cu-A are not cytotoxic [109, 111, 112], while A preparations 
generated under sub-stoichiometric amount of Cu
2+
, that favor amyloid formation, will 
significantly enhance the cytotoxicity [23].  It seems clear that in vivo, levels of both A and 
Cu
2+
 are lower than for the in-vitro studies, thus Cu
2+
 is likely to exclusively accelerate fiber 
formation in-vivo. 
 
6.2) Mechanism of Cu
2+
 accelerated amyloid formation:  
So what is the mechanism by which Cu
2+
 ions accelerate the rate of fiber formation? A range of 
possible mechanisms by which metal ions might influence fiber formation kinetics are 
discussed in general terms in section 2.  At micromolar concentrations of A, Cu2+ does not 
form crossed-linked species [56, 57, 117].  The Cu
2+
 coordination geometry is identical in the 
monomer and fiber [53, 54]. Most importantly, the affinity of Cu
2+
 for A is identical for 
monomer and fiber, suggesting the same complex forms without cross-linking [53].  
Furthermore, without a reductant there are no reactive oxygen species generated and therefore 
no di-tyrosine cross-linking [27], consequently copper bridging to form cross-linked A as a 
possible mechanism of accelerated fiber formation, is ruled out. The conformational changes in 
A upon Cu2+ binding are small and outside of the fiber core [53, 56], it therefore seems 
unlikely that the Cu
2+
 coordination triggers the A misfolding directly by a change in main-
chain conformation. However, intermolecular self-association is strongly influenced by the net 
charge of the protein.  As A approaches its isoelectric point, a pI of 5.3, and an overall neutral 
charge, its solubility decreases [118, 119]. Furthermore, as the pH drops from 8 to 6 the rate at 
which fibers form significantly increases, with lag times (tlag) reduced by more than four-fold 
[23].  The pH dependence of the fiber growth rates bears a strong resemblance to the 
protonation state of the histidine residues (pKa 6.7) and the N-terminal amino group (pKa 7.9) 
within A consequently, the net charge of A is crucial to its amyloidogenicity. 
 
As with pH, the binding of metal ions will also change the net charge of A.  Cu2+ (and Zn2+) 
ions bind to the three histidine residues within A [10, 22, 46, 53, 54, 56, 57], at pH 7.4 A’s 
histidine residues are predominately (80 %) deprotonated and neutrally charged, thus 
coordination of Cu
2+
 (or Zn
2+
) to A's histidines adds two positive charges.  Adding positive 
charge to A at pH 7.4 makes the A peptide complex more neutral in overall net charge, and 
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therefore more prone to self-association, with the result that fiber growth times are almost 
halved.  It seems the most probable cause of Cu
2+
 ion accelerated fiber formation kinetics is the 
reduction in the net charge of A which promotes self-association. It is notable the metal 
coordination involving amide ligands (as is the case for PrP and Syn, see Figure 3), will result 
in deprotonation.  Thus the net change in charge upon Cu
2+
 binding may be small, or even 
cause a loss of positive charge.   
 
6.3) Cu-A and Cell Toxicity  
There are a number of studies investigating the effect of Cu
2+
 on the cell-toxicity of A [23, 
109, 112, 120-122]. At first glance these studies seem to report conflicting observations.  In 
some studies enhanced cytotoxicity is reported for Cu
2+
 plus A [121], while others report that 
Cu
2+
 has a protective effect on A toxicity [109, 112].  When the nature of the A preparation 
is considered (e.g. amorphous aggregates, monomers or fibers) the various studies become 
more consistent.  When supra-stoichiometric levels of Cu
2+
 are used, amorphous aggregates are 
generated, which are not cytotoxic, but when sub-stoichiometric amounts of Cu
2+
 are used, A 
fibers are generated and the presence of Cu
2+
 will significantly enhance the cytotoxicity.  Sarell 
et al have shown both the protective effect of Cu
2+
 at supra-stoichiometric levels together with 
enhanced cytotoxicity for sub-stoichiometric levels [23], as shown in Figure 6.  In vivo, A is 
present at lower levels than for the in vitro experiments and sub-stoichiometric levels of Cu
2+
 
are the more physiologically relevant case, suggesting a role for Cu
2+
 ions in enhancing A’s 
cytotoxicity. 
 
The mechanism by which A is toxic to cells (irrespective of the presence of Cu2+ ions) is hotly 
debated [32, 123]. It is often suggested that A acts at the membrane surface to disrupt its 
integrity; thinning or forming pores in the plasma membrane to cause membrane leakage and 
loss of cellular Ca
2+
 homeostasis.  One popular hypothesis is that the membrane integrity is 
compromised by lipid peroxidation from reactive oxygen species (ROS), which is a feature of 
the pathogenesis of AD and other protein misfolding diseases [124]. One key observation 
shows that hydrogen peroxide mediates A toxicity and the anti-oxidant enzyme catalase 
protects cells from A toxicity [40, 121, 122]. Fenton redox cycling of copper or iron ions are a 
likely source of extra-cellular H2O2 [125].  Indeed Cu
2+
 bound to A will readily generate 
hydroxyl radicals and H2O2 in the presence of a physiological reductant such as ascorbate [28, 
121, 126, 127].  Furthermore, metallothionein-3 (MT3) will competitively bind copper ions in a 
redox-inactive form, which will suppress A’s cytotoxicity [120].  An interesting recent study 
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has highlighted the role of copper bound prion protein in mediating A neuronal toxicity [42] 
and is discussed further in see section 10.3. 
 
The precise reasons for the enhanced cytotoxicity of A in the presence of Cu2+ ions are not 
clear.  A could bind Cu2+ promoting oligomer and fiber formation, which may result in an 
increase concentration of Cu
2+
 ions at the neuronal cell surface in a redox active form, where 
Cu
2+
 would generate toxic hydrogen peroxide and hydroxyl radicals. A oligomers are found 
clustered at synaptic terminals [128] and cause memory loss due to synaptic failure [31].  The 
observation that the anti-oxidant protein catalase and the Cu
2+
 binding metallothionein-3 (MT3) 
are protective to cell-culture, strongly supports this hypothesis [40, 120-122]. Alternatively, the 
Cu
2+ 
ions could alter the morphology of the fiber or increase the level oligomers relative to 
fibers, promoting an enhanced toxic effect to the cells. The heightened toxicity may be due to a 
combination of ROS generation and changes in the morphology of fiber/oligomer generated 
with sub-stoichiometric amounts of Cu
2+
 ions. Cytotoxicity studies by Sarell et al suggest that 
toxicity is not exclusively due to ROS as A toxicity does not increase commensurately with 
increased loading of Cu
2+
 ions [23].  Thus the ability of Cu
2+
 to promote fiber growth (and by 
inference the interplay between monmer, oligomer and fiber) and the ability of Cu
2+
 to affect 
fiber morphology appears to be the significant factor in Cu
2+
 / ROS promoted A cell toxicity.   
 
6.4) Zn
2+
 A fiber inhibition, oligomer promotion 
If Cu
2+
 ions accelerate fiber formation at sub-stoichiometric levels, what about other divalent 
metal ions? Interestingly, Zn
2+
 ions appear to completely inhibit fiber formation even at low A 
(3 micro-molar) and zinc ion levels [23].  Indeed millisecond pulses to Zn
2+
 ions (mimicking 
pulses of Zn
2+
 that occur at the synapse) can stimulate A aggregation and inhibit fiber 
formation [129].  A recent paper by Chen et al also showed little ThT fluorescence in the 
presence of Zn
2+
, even at sub-stoichiometric levels of Zn
2+
 [24].  Unlike Cu
2+
, TEM images of 
Zn
2+
 loaded A showed no fibers were generated. This may be due to the very different 
complex (at micromolar concentration) between the two metal ions.  Cu
2+
 ions form an intra-
molecular complex with A [53, 54, 56, 57], while at micromolar concentrations of A, it 
appears Zn
2+
 will form an inter-molecular complex; cross-linking between histidine residues on 
multiple A molecules [22, 46, 63, 130].  It is probable that a cross-linked Zn2+-A species will 
inhibit amyloids forming by interfering with the regular cross-beta assembly.  These in vitro 
experiments were performed at 3 micromolar concentrations of A.  It may be that in vivo, 
where A is much less concentrated (0.1 nanomolar), inter-molecular Zn2+ complexes may be 
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less favored and thus the Zn
2+
 might, like Cu
2+
, form only intra-molecular complex with 
histidine side chains and so accelerate fiber formation in vivo with a similar mechanism to Cu
2+
 
ions. 
 
Interestingly, A aggregates generated by the presence of Zn2+ showed a positive binding in a 
dot-blot antibody assay for A oligomers [24].   In contrast, the A11 antibody which 
recognized A oligomers did not bind with metal free A or A loaded with Cu2+ or Fe3+ [24].  
TEM images of the Zn
2+
 loaded A showed ring-shape, pore-like oligomers in the pellet of 
Zn
2+
 promoted A aggregates.  The Zn2+ induced oligomers resemble previously characterized 
annular protofibrils [33].  It remains to be established if the Zn
2+
 promoted oligomers will 
affect cell membrane integrity.   
 
6.5)  Fe
3+
-A:  
Although Fe
2+
 binds specifically to A [131] the affinity of Fe3+ for A appears to be very 
weak [132, 133] and thus one might have predicted little evidence for a link between iron 
homeostasis and AD, however the opposite is the case.  Significantly in both fly [134], [26] and 
mice [135] models of AD, iron regulation has been shown to exacerbate the disease phenotype.  
For A fibrils generated in the presence of Fe3+, the rate of formation is inhibited [26] 
particularly at above stoichiometric amounts of Fe
3+
 [24].  A study by Crowther et al has 
suggested that Fe
3+
 influences the morphology of A fibers with shorter more curved fibers 
generated, and it is suggested that it may be this which influences A toxicity in the fly [26]. 
 
6.6) Ca
2+
 A   
Ca
2+
 is found at very high concentrations extra-cellularly, relative to transition metal ions, 
typically at 2 millimolar in the extra-cellular space. Interestingly in vitro Ca
2+
 can accelerate 
A fiber formation [136].  Ahmad et al have shown that at physiological levels of Ca2+ (2 
millimolar), the kinetics of A(1-42) amyloid fiber formation is greatly accelerated, doubling 
the lag-time [137]. Surprisingly, no such effect was observed for Ca
2+
 addition to A(1-40) 
solutions [137].  Ca
2+
 is a hard metal ion and coordinates via oxygen ligands.  There are six 
Asp/Glu residues, largely in the N-terminal half of A with which Ca2+ can coordinate.  It is 
notable that Ca
2+
 (like Cu
2+
) binding will add positive charge to A at pH 7.4, making it more 
neutrally charged and, therefore, more prone to self-association.  Whether Ca
2+
 homeostasis has 
an influence on the pathology of AD is not established.  Although Ca
2+
 is an abundant bulk 
metal ion, it is not clear if AD pathology will be strongly influenced by fluctuations in Ca
2+
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levels outside the cell.  However, the high extra cellular levels of Ca
2+
 may influence the 
critical concentration for fibril formation and could explain why sub-nanomolar levels of 
extracellular A may be sufficient to cause fibers to form in vivo. 
 
6.7)  Al
3+
 A:  
Fibril growth kinetics, using ThT, indicate little effect on the rate of fiber formation for Ab:Al
3+
 
ratios of 1:1 or 1:4.  At higher levels of Al
3+
, fiber formation is strongly inhibited [24].  The 
influence of Al
3+
 on AD aetiology is reviewed in detail elsewhere in the special issue. 
 
7) Metal ions and amyloid formation in transmissible spongiform encotholthapies (TSE) 
Although the coordination geometry and affinity of Cu
2+
 binding to PrP
C
 has been studied 
extensively [16, 50, 51, 85, 138, 139], there are surprisingly few studies of Cu
2+
 binding to 
prion protein fibers or studies on the influence of metal ions on the kinetics of fiber formation.  
It has been shown that Cu
2+
 promotes aggregation of PrP, lowers PrP solubility and promotes 
self-association [140-142].  In addition, Cu
2+
 ions can convert the PrP
C
 into a protease-resistant 
species [140, 143-145], which is a feature of PrP
Sc
. Furthermore, Cu
2+
 binding encodes features 
that correlate with various strains of prion disease [20].  There is a report using dynamic light 
scattering that indicates at millimolar levels, Cu
2+
 promotes oligomers of PrP, while the 
presence of amyloids were not well characterized [140].  Furthermore, Cu
2+
 has been shown to 
promote the formation of soluble oligomers at pH 5, these Cu-PrP oligomer will reduce cell 
viability in a SKNSH cell line [146]. 
 
A careful study by Baskakov et al showed that at 1 micromolar Cu
2+
 levels, 1:1 ratio with PrP
C
, 
there appears to be little effect on prion protein fiber kinetics.  At 10 mole equivalents, Cu
2+
 
fiber formation was inhibited and at 100 micromolar Cu
2+
 (1 micromolar PrP), no fiber 
formation was observed. [147].  This behavior has some parallels with Cu
2+
 binding to A as 
surpra-stoichiometric ratios of Cu
2+
 cause self-association of A into amorphous aggregates 
and so inhibit fibrillization [23].  As with all in vitro studies there remains a question as to how 
well the in vitro, observations reflect the in vivo situation. Cu
2+
 induced  self-association of PrP 
in the form of amorphous aggregates hints at the possibility that in vitro where PrP
C
 is at lower 
concentrations anchored to the plasma membrane surface, fibrillization might occur rather than 
aggregation, as is the case for A [23].   Interestingly, the same Baskakov et al study showed 
that once amyloid fibers are formed, the presence of Cu
2+
 can affect the morphology of the 
fibers.  Cu
2+
 enhances PK-resistance of preformed fibrils and initiates aggregation of preformed 
PrP fibrils into larger plaque like clumps [147].  Baskakov et al also showed that Zn
2+
 at 1:1 
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ratios has little effect on fibrillization, but at higher levels inhibited fiber formation, but to a 
lesser extent than Cu
2+
 ions. Mn
2+
 had little effect on fibrillization rates even at 100 mole 
equivalents [147].   
 
8) Metal ions and amyloid formation of Syn in Parkinson’s disease (PD) 
Metals have also been proposed as triggers for other misfolding and assembly diseases, 
including Parkinson’s disease (PD). The acceleration of the kinetics of fiber formation of Syn 
was described over ten years ago [104, 148, 149].  However, these early studies used high 
levels of metal ions, higher than those normally found physiologically.  Using 0.5-5 mM 
concentrations, a number of transition metal ions increased the rate at which Syn formed 
amyloid fibers.  Significantly, subsequent studies by Fernandez et al, using much lower 
concentrations of Cu
2+
 ions also accelerated fiber formation. [89] They showed that a 1:1 
binding of Cu
2+
 with 100 micromolar of Syn will significantly reduce the lag-time of 
fibrillization.  A follow up study investigating the effect of other divalent transition metal ions; 
Mn
2+
, Fe
3+
, Co
2+
 and Ni
2+
 showed little or no effect on the kinetics of Syn fibril formation 
using 1:1 metal:Syn ratios [99].  These metal ions have very low affinities for Syn in the 
millimolar range, and as a consequence, at these more physiologically relevant levels (100 
micromolar Syn) there are few of these metal ions bound to Syn.  Furthermore, Cu2+ will 
exacerbate the cytotoxicity of Syn as assessed by additions of Cu-Syn to cell culture [150]. 
 
9) Metal ions and amyloid formation in other protein misfolding diseases   
Metals have also been proposed as triggers for other misfolding and assembly diseases such as 
dialysis-related amyloidosis [21].  Here Cu
2+
 binds to 2-microglobulin (2m) and causes a key 
cis-trans isomerization of a proline at position 32.  Another protein perturbed by metal ions is 
the human islet amyloid peptide (hIAPP); a highly amyloidogenic peptide found in the islet 
cells of patients with type-II diabetes.  hIAPP is toxic to -cells and is linked to a loss of insulin 
secretion. Although highly amyloidogenic, hIAPP is safely stored in the secretory granules at 
high concentrations.  Interestingly, unusually high millimolar levels of Zn
2+
 are found in 
pancreatic -cells.  It has been shown that these high levels of Zn2+ will inhibit hIAPP fiber 
formation.  This raises the possibility that zinc has a protective role in hIAPP amyloid 
formation associated with type-II diabetes [151, 152]. Cu
2+
 will also inhibit hIAPP amyloid 
formation [153]. Aberrant metal binding is also implicated in the misfolding and accumulation 
of Cu-Zn-superoxide dismutase (SOD) in amyotrophic lateral sclerosis (ALS) [154].  While 
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Huntington’s Disease, a poly-glutamate protein misfolding disease, has also been linked with 
copper promoted aggregation [155]. 
 
10) Metal ion homeostasis at the synapse and metal ion affinities for A and PrP 
From the previous sections it clear there is now compelling data to show that metal ions 
influence, and can accelerate fiber formation and enhance cytotoxicity.  However, a role for 
metal ions in protein misfolding diseases remains controversial, as it is often believed that the 
affinity of A and PrP for metal ions is not sufficiently high to be physiologically relevant.  
This section highlights some pertinent features of metal ions at the synapse and protein 
affinities.  
 
10.1)  Cu
2+
 and Zn
2+
 at the synapse:   
Aand PrP are found concentrated at the synaptic cleft, as shown in Figure 7.  PrPC is found 
bound to the extra-cellular membrane, while A is released at the synapse [128, 156, 157].  The 
concentrations of metal ions at the synapse are therefore of particular interest as it is now 
established that Zn
2+
 and Cu
2+
 are released at the glutamatergic synapse in the cortex and 
hippocampus.  There are now a number of excellent reviews describing what is known about 
Zn
2+
 and Cu
2+
 at the synapse [8, 158-160]. This synapse is the site of long-term potentiation, 
which is responsible for memory formation and it is here that A amyloid deposits are first 
observed in AD patients.  Zn
2+
 ions are released, possibly with glutamate, during 
neurotransmission [161], fluxes of Zn
2+
 released into the extracellular space may be as free 
ionic form or as exchangeable Zn
2+
 at 10-30 micromolar levels [162].  It is believed Zn
2+
 will 
reach even higher levels during brief synaptic release events, perhaps 100-300 micromolar 
[158, 163, 164].  Similarly there is a release of exchangeable copper post-synaptically 
following activation of the NMDA receptor [165-167], Figure 7.   It is believed Cu
2+
 reaches 
levels of 15 micromolar [168], some have reported even higher fluxes of Cu
2+
 from 20-250 
micromolar, during neuronal depolarization [17, 169]. 
 
10.2)  A and PrP affinity for metal ions:   
A role for metal ions in protein misfolding is often disputed on the basis of insufficient metal – 
protein affinity.  Affinity measurements are a potentially difficult area and are often plagued 
with conflicting observations.  An excellent review that highlights some of the common 
potential pitfalls in metal affinity measurements and calculations see [170].  For example, often 
the effect of competing buffers, multiple binding modes of competing ligands, the solubility of 
the metal ion and competing ligand, or its oxidation state as well as the pH dependence on the 
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affinity are sometimes incorrectly understood or simply not considered.  There have been 
numerous metal affinities reported for A, PrPC and Syn over the past decayed but now 
perhaps a consensus is emerging.  Table 2 highlights some key measurements of conditional 
dissociation constants at pH 7.4 for copper binding to A , PrPC andSyn. Affinities shown in 
Table 2 are by no means a comprehensive list, it’s purpose is to highlight some of the key 
recent studies.  For a more complete review of this area and a discussion of conditional binding 
constant that take into account the competitive effects of buffers , see Faller et al [46]. 
 
The affinity of Cu
2+
 for A has been calculated using 3 different competing ligands; very 
similar Kds are observed for monomeric and fibrilar A for all 3 competing ligands.  Setting the 
conditional dissociation constant, pH 7.4, at 54 +/-5 picomolar (54 x 10
-12
 M) [53].  The use of 
three different competitors for Cu
2+
 that all indicate almost identical affinities for the Cu
2+
-A 
complex indicates that a ternary complex, which might complicate the determination of a Cu
2+
 
affinity, does not from.  Hatcher et al [171] and Tougo et al [172] have reported Cu
2+
 affinities 
a single order of magnitude weaker.  
 
Extra-cellular monomeric A levels are thought to be 0.1-1 nanomolar [173, 174], while A 
levels are higher in plaques and at the synapse.  Extra-cellular Cu
2+
 levels in the brain 
interstitial fluid are typically 100 nM. A picomolar affinity for Cu
2+ 
allows A to compete for 
these 
 
ions with other extracellular Cu
2+ 
chelators, especially at the synapse during neuronal 
depolarization where fluxes of Cu
2+
 are reported to be 20-250 micromolar and A is localized 
[169].    
 
Zn
2+
 affinities for A are relatively weak, with 1-20 micromolar dissociation constants reported 
[46, 175] .  However, it is known that exchangeable or free Zn
2+
 ions can reach levels as high 
as 30-300 micromolar at the glutamatergic synapse [158, 163, 164].  Thus Zn-A interactions 
may also be physiologically relevant. 
 
PrP
C
 has as many as six binding sites with 30-100 nanomolar affinities [85].  Others have 
reported Kds to within one or two orders of magnitude [72, 73, 176].  PrP
C
 is situated at the 
plasma membrane of the synapse, with 6 potential Cu
2+
 binding sites on the flexible N-terminal 
domain, it must, therefore, make it a good buffer for micro-molar fluxes of Cu
2+
 at the synapse.  
Cu
2+
 is bound to PrP
C
 in vivo [17] and furthermore Cu
2+
 and Zn
2+
 will trigger endocytosis of 
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PrP
C
.  Rapid turnover of PrP and increased oxidative stress associated with PrP knockouts 
suggest that PrP might have a protective anti-oxidant role [29, 177, 178]. 
 
To make a prediction as to the likely levels of metal binding to PrP and A in-vivo we also 
need to consider the levels of other metallo-proteins at the synaptic cleft. Metallothionein3, 
(MT3) found within neurons may be to buffer synaptic fluxes of Cu
2+
 and Zn
2+
 as it is released 
in the cleft by near-by astrocytes [179].  MT3 binds Cu
2+
 in a redox inactive state and can 
protect against the toxic effects of Cu
2+
 and Zn
2+
 [120, 158].  Interestingly, MT3 levels are 
suppressed in AD patients [180], although this has been disputed [181].  In this situation, the 
buffering of these metal ions may become swamped and therefore available for binding A and 
PrP.  Humans serum albumin highly concentrated in blood plasma, at 640 micromolar, and 
binds extra-cellular Cu
2+
 with a 1 picomolar affinity.  However, the concentration of albumin is 
considerably lower in the CSF, (3 micromolar) and so may be swamped by spikes of Cu
2+
 at 
the synapse during neuronal depolarization, Figure 7.   
 
10.3) A toxicity mediated by copper bound PrPC at the synapse  
Interestingly, both PrP
C
 and A are concentrated at the synapse and there is now strong 
evidence to link A neurotoxicity with the presence of PrPC [182, 183].  A toxicity in mice 
models of AD requires the presence of PrP
C
 [182].  Indeed PrP knockout mice can develop A 
plaques but not neurotoxicity [184].  Interestingly PrP
C
 selectively binds to Aβ oligomers [185, 
186]. A molecular mechanism for the PrP
C
 dependent A toxicity has recently been proposed 
which indicates A disrupts copper homeostasis at the synapse which is required for normal 
PrP
C
 dependent inhibition of excessive N-methyl-D-aspartate receptors (NMDAR) activity 
[42].   NMDA receptors mediate critical CNS functions, a physiological role for PrP
C
, has been 
proposed that limits excessive NMDAR activity that might otherwise promote neuronal 
damage [187].  Significantly, PrP
C
 only affects the NMDA receptor in a copper-loaded state 
[42].    There is evidence to suggest that the oligomeric form of A released at the synapse, 
with a picomolar affinity for Cu
2+
, may disrupt Cu
2+
 binding to PrP
C
 and so, in part at least, 
mediate neuronal and synaptic injury [42]. 
 
11) In vivo evidence for a link between metal ions and protein misfolding diseases:   
From the previous section it is clear that the affinities of A and PrP for Cu2+ and Zn2+ ions are 
sufficiently tight for them to be physiological relevant, particularly when fluxes of these ions 
are released at the synapse during neuronal depolarization.   In this section evidence, from in 
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vivo studies, in support of a role for metal ions in a number of protein misfolding diseases are 
highlighted.  
 
11.1) Alzheimer's disease (AD):  
Copper: In vivo studies using a Drosophila model of AD have shown that impaired copper 
homeostasis enhances the toxic effects of A [188], while a rabbit model of Alzheimer's 
disease showed rabbits fed copper in a high cholesterol diet develop amyloid plaques and 
learning deficits [189].  In contrast, transgenic mice have shown a reduced AD pathology with 
increased intra-cellular copper levels [190-192].  Interestingly Cu
+
 will also bind to A and 
may therefore influence fiber formation [193].  Understanding the interplay between intra and 
extra cellular copper and its effect on A will be essential for a more complete picture of 
copper related AD pathology [194].  It appears that AD may be characterized by an increase in 
labile extra-cellular pool of Cu
2+
 ions [195]. 
 
Zinc: Zn
2+
 is concentrated in synaptic vesicles with the assistance of a specific zinc transporter, 
Zn-T3.  Significantly, a mouse model of AD with Zn-T3 knocked out do not develop amyloid 
plaques in the brain [196].  Furthermore, MT3 is released by astrocytes at the synaptic cleft and 
have a role in buffering Cu
2+
 and Zn
2+
.  Interestingly, MT3 (GIF) levels are reduced by an order 
of magnitude in AD patients [180] although this is contested [181]. 
 
Iron: Significantly, in both fly [26, 134] and mice [135] models of AD, iron regulation has 
been shown to exacerbate the disease phenotype; reducing fly longevity and increasing rough 
eye. In particular, ferritin, the iron storage protein, will influence the disease phenotype [26, 
134].   
 
11.2) TSE:  
The relationship between metal ions and prion disease have been reviewed [50, 51, 138, 139]. 
A feature of prion disease are metal imbalances [19]. Copper shows an increase in toxicity for 
PrP knockout mice and exacerbates disease in a mouse model of familial CJD [197].  Increased 
copper in the diet of mice raises PrP
C
 levels; although counter intuitively survival times after 
scrapie infection are reduce with mice fed a low copper diet [18].  Furthermore, when isolated 
from diseased brain, PrP
Sc
 has been found to be occupied with Cu
2+
 ions [20]. Different strains 
of prion disease may be generated depending on the presence, or absence, of Cu
2+ 
ions [20]. 
PrP knockouts show altered metal ion homeostasis in the mice brain [198].  Protease resistance 
in PrP is induced upon Cu
2+
 binding [144, 145].  Younan et al have recently shown Cu
2+
 ions 
  
23 
 
 
can destabilize the fold of PrP
C
. The free energy of folding is lowered by 2 kJ/mol and 
therefore may make the transition to misfolded PrP
Sc
 more thermodynamically favorable [25].  
A form of familial prion disease is linked to an increased ability to bind Cu
2+
 ions with 
additional octarepeats present, while Cu
2+
 binding to the amyloidgenic fragment of PrP is 
linked to increased neurotoxicity [199-201]. In addition, oxidative modifications of PrP, 
generated by copper catalyzed Fenton reaction has been linked to prion disease [29, 30, 202].  
Significantly, copper ion chelation therapy will delay onset of scrapie in mice [203].   
 
11.3) Parkinson’s Disease (PD) :  
An increased risk of developing PD has been linked to industrial exposure to heavy metal ions 
[204].  Elevated levels of Cu
2+
 have been reported in the cerebrospinal fluid of PD patients 
[14], in addition iron deposits have been found in the lewy bodies [15].  Further details are 
discussed elsewhere in this special issue. 
 
12) Is there a shared metal associated mechanism of amyloidoses? 
It is believed that all proteins under the right conditions will form amyloid structures with a 
shared generic cross-beta structural motif [1]. Perhaps the mechanism by which metal ions 
accelerate fiber formation is also shared. Sarell et al has proposed that metal accelerated fiber 
formation for A might be driven by electrostatics [23]. At pH 7.4 metal ion coordination via 
imidazole side chains will cause the net charge of the protein to be more positive.  However 
this is not always the case, if coordination is dominated by amides, as in the case of for some of 
the modes of coordination of Cu
2+
 to the prion protein (Figure 3) then Cu
2+
 binding will 
actually reduce the net charge, due to the loss of up to three protons upon forming the complex.  
Thus the change in net charge of the protein upon metal coordination is dependent on the type 
complex formed.  
 
Theoretical pI’s for a number of amyloidogenic proteins are given in Table 3. A and Syn, 
have acidic pI’s, 5.3 and 4.6 respectively.  Using our understanding of the coordination 
geometry it appears Cu
2+
 at pH 7.4 will make A more neutrally charged.  However the first 
equivalent of Cu
2+
 binding at the N-terminus of -Syn will have little effect on the overall 
charge due to the displacement of two protons, one from the amino group and one from an 
amide (Figure 3).  The prion protein possesses a basic pI, 9.8 so a neutral pH PrP is already 
positively charged, however Cu
2+
 binding dominated by amide proton displacement will make 
PrP more neutrally charged binding centred at His
111
 or His
96
 of PrP.  Unlike A and Syn, 
Cu
2+
 binding to PrP have been reported to inhibit fiber formation [147].     
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The acceleration of fiber formation upon metal bind may be a combination of a number of 
effects, and a change in net charge is just one of these.  It does not appear that all metal 
associated amyloidosis are related to a change in net charge and increased self-association. 
Cu
2+
 binding to 2m appears to be closely related to a structural rearrangement induced by 
Cu
2+
 binding rather than a change in net charge [21].  While in SOD, it is the destabilization of 
the native fold of the protein due to a point mutation and a loss of a zinc ligand that destabilizes 
the native protein fold [154]. 
 
13) Concluding remarks 
Metal ions are capable of affecting amorphous aggregation, oligomerization and fibrillization 
of a number of amyloidogenic proteins associated with protein misfolding [21, 89, 147, 151].  
Furthermore, metal ion homeostasis, particularly at the synapse, where Zn
2+
 and Cu
2+
 are 
released as a labile pool is now being recognized as a potential risk-factor in these multi-
factorial diseases.   In particular, for Alzheimer’s disease (AD), it is now established that A 
has a tight, physiologically relevant, picomolar affinity for Cu
2+ 
[53]. Furthermore, Cu
2+
 
binding significantly accelerates the rate of fiber formation and enhances cytotoxicity in cell 
culture [23]. These observations are supported by in vivo studies in animal models of AD that 
implicate Cu
2+
 impaired homeostasis in promotion of the disease [188, 189].   A recent study 
suggests the toxicity of A is mediated by both copper ions and the prion protein [42].  This is 
a particularly exciting new development linking copper homeostasis at the synapse with two 
amyloidogenic proteins, and is set to generate a major paradigm shift in our understanding of 
Alzheimer’s disease.   
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Figure Captions 
Figure 1: Potential mechanisms by which metal ions can perturb protein fiber formation: 
i) Metal induced conformational change. ii) Metal induced cross-linking. iii) Metal induced 
neutral net charge iv) Metal induced change in fiber morphology. v) Metal induced change in 
protein stability. 
 
Figure 2: Fibers versus amorphous aggregates. Fibers are in equilibrium with, oligomers, 
monomers and amorphous aggregates and there relative proportions are interdependent.  
 
Figure 3: Cu
2+ 
coordination to A, PrP and Syn. These are models adapted from [53, 55] 
for A [16] for the prion protein modes of coordination (mouse sequence numbering) and [94] 
for -synuclein.  
 
Figure 4: Fiber growth kinetics. Nucleation–polymerization reaction causes a sigmoidal 
growth curve with a lag-phase and elongation.  Fiber formation is initially very slow until 
nucleating seeds are generated; this initiate’s rapid fiber generation until equilibrium with low 
amounts of protein monomer is reached. Agitation will cause fragmentation and additional 
secondary nucleation and a reduced lag-phase. 
 
Figure 5: Cu
2+
 accelerates fiber growth. (a) Average of 9 growth curves recorded on two 
separate occasions, apo in red, 1 mole equivalent Cu
2+
 in blue. The fluorescence ThT signal is 
normalized at maximal intensity. A(1-40) 5 micromolar, HEPES buffer 50 mM, 160 mM 
NaCl at 30 
o
C.  (b) Time to reach half-maximal fluorescence (t50) in two experiments with 0 
(red), 1 (mid-blue) or 0.5 (dark blue) mole equivalents of Cu
2+
 ions. The presence of Cu
2+
 
typically halves the time taken to form fibers. Error bars are for standard error (s.e.m.) from 
nine traces. P= 0.001 indicated by ***. Adapted from [23]. 
 
 Figure 6: Cell viability, Cu
2+
-A  is more cytotoxic than A.  A(1-42) as preformed fibrils, 
3 micromolar, with and without the presence of 1.5 micromolar Cu
2+
 were added to PC12 cells. 
Cu
2+
 was added to the cells alone to test Cu
2+
 toxicity. Blank is buffer only. All preparations 
were incubated with the cells for 24 hrs then 10% (v/v) Alamar Blue was added. The data 
shown here is after total incubation for 70 hrs. Error bars are standard error (s.e.m), n=3.  P= 
0.001 indicated by ***.  Adapted from [23]. 
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Figure 7:  Zn
2+ 
and Cu
2+ 
at the synapse.  Exchangeable Zn
2+ 
 is released with glutamate from 
vesicles at gutamergic synapse after neuronal excitation, 30-100 micromolar spikes of Zn
2+ 
 
may be reached. Cu
2+ 
 is released postsynaptically after NMDA receptor activation, 15 
micromolar or more fluxes of Cu
2+ 
 are reported.  A is cleaved from APP in to the lumin of 
vesicles as it travels down the axon, A is then released at the presynapse .  PrP is anchored to 
the plasma membrane concentrated at the presynapse.  ZnT-3 and the menkes protein, ATP7a, 
are key protein responsible for trafficking Zn
2+
 and Cu
+
 respectively into vesicles.  
Metallothionein3 (MT3), released from astrocytes may serve as a buffer for the fluxes of Zn
2+ 
 
and Cu
2+ 
 but may be depleted in Alzheimer's disease. 
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Table 1:  The effect of Cu
2+
 on A fiber formation.   
 
Stoichiometry     Peptide  Concentration   Technique  Observation   Ref 
[Cu2+]/ [A]  (micromolar) 
 
  0.2  A40) 5  ThT Accelerate fiber kinetics [23] 
  0.5  A40) 5  ThT Accelerate fiber kinetics [23] 
 1  A40) 5  ThT Accelerate fiber kinetics [23] 
 0.5  A42) 3   ThT Promotes fibers  [23] 
 2  A40) 5  ThT No fibers  [23] 
 0.5  A40) 50   ThT No fibers  [23] 
 
 2  A40) 10   ThT No fibers  [109] 
 2  A42) 10   ThT Reduced fibers  [109] 
 
 0.5  A42) 5   ThT Reduced fibers  [112] 
 1.0  A42) 5   ThT No fibers  [112] 
 
 1  A40) 25   ThT Reduced fibers  [24] 
 0.2  A40) 25   TEM Fibers observed  [24] 
 
 0.4  A40) 50   ThT No fibers  [110] 
 0.2  A40) 50   ThT Reduced fibers  [110] 
 
 1  A42) 40   ThT Reduced fibers  [115]  
 
 <1  A42) --   TEM Fibers observed  [27] 
 >1  A42) --   TEM No fibers  [27] 
 
 1  A40) --  TEM Fibers observed  [116] 
 2  A40) --  TEM No fibers  [116] 
 
 0.5  A42) --   AFM No fibers  [113] 
 
 0.7  A40) 2.5   Centrifugation   Increased precipitation [107] 
 
 1  A40) 20   Absorption Increase turbidity  [108] 
 
 
The data is largely consistent with supra-stoichiometric amounts of Cu
2+
 or high concentration 
of A generating amorphous aggregates. While at physiologically relevant lower 
concentrations and substoichiometric Cu
2+
 amyloid fibers are observer and their rate of 
formation is accelerated. 
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Table 2: Copper
2+
 affinities for synaptic amyloidogenic proteins.   
 
Protein         Conditional Kd,  pH 7.4 Reference 
 
Amyloid beta peptide (A)  54 picomolar [53] 
  400 picomolar [171] 
  35 nanomolar (* 625 picomolar)  [172] 
 
Prion protein (PrPC)**  30 nanomolar  [85]   
  3  nanomolar  [72]  
  0.1 nanomolar [73] 
 
Alpha-synuclein (Syn)  0.4 nanomolar [97] 
  0.2 nanomolar  [98] 
  0.1 nanomolar [94] 
 
Data presented are for conditional dissociation constant at pH 7.4.   *Correction made for the 
buffer used.   **PrP
C 
binds up to six Cu
2+ 
ions, a weaker affinity of 100 nanomolar is reported 
for Cu
2+
 binding to single octarepeats.   
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Table 3:  pI’s for amyloidogenic proteins and the effect of Cu2+ on fiber growth rates. 
 
Protein      pI      Effect of Cu
2+
 on  Reference 
      Fiber growth kinetics   
 
Amyloid-beta peptide (A) 5.3  Accelerate  [23] 
Alpha-synuclein (Syn)  4.4  Accelerate  [89] 
2-microglobulin (2m)  6.5  Accelerate  [21] 
Human Prion protein (PrP) 9.8  Inhibit   [147] 
islet amyloid poly peptide (IAPP) 8.9  Inhibit   [153] 
 
For protein with acid pI’s amyloid fiber formation is accelerated while for basic proteins it is 
inhibited. 
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